Esperion Therapeutics (NASDAQ:ESPR) Downgraded to “Hold” Rating by StockNews.com

StockNews.com downgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a buy rating to a hold rating in a report published on Friday.

Other equities analysts have also issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research report on Friday, November 8th. Needham & Company LLC lowered their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $8.17.

Esperion Therapeutics Stock Performance

Shares of ESPR stock opened at $2.15 on Friday. The stock’s 50 day simple moving average is $1.97 and its 200 day simple moving average is $2.14. Esperion Therapeutics has a twelve month low of $1.15 and a twelve month high of $3.40. The company has a market capitalization of $423.63 million, a price-to-earnings ratio of -3.31 and a beta of 0.96.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ESPR. Capital Advisors Wealth Management LLC boosted its position in shares of Esperion Therapeutics by 22.9% in the second quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 5,000 shares during the period. Boomfish Wealth Group LLC boosted its holdings in Esperion Therapeutics by 17.1% in the 3rd quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 5,102 shares during the period. Summit Financial LLC grew its position in Esperion Therapeutics by 26.4% in the 2nd quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 6,823 shares during the last quarter. National Bank of Canada FI increased its holdings in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 10,225 shares during the period. Finally, SG Americas Securities LLC raised its position in shares of Esperion Therapeutics by 45.3% during the second quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 11,658 shares during the last quarter. 47.39% of the stock is owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.